mefenamic acid has been researched along with Neoplasms in 5 studies
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Resistance to anticancer medications often leads to poor outcomes." | 1.46 | Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity. ( Kasamatsu, A; Minakawa, Y; Okamoto, A; Sakamoto, Y; Shiiba, M; Takiguchi, Y; Tanzawa, H; Uzawa, K; Yamagami, H; Yamamoto, A, 2017) |
| "Indomethacin was found to have significant augmenting effect on LAK cell activity at the concentration of 5 x 10(-5) M, whereas aspirin and ponstan did not show the same effect at the same concentration." | 1.29 | The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression. ( Chao, TY; Chu, TM; Ting, CS; Yeh, MY, 1993) |
| "Plasminogen level in cancer patients was significantly higher than in healthy subjects." | 1.27 | [Mechanism of formation of blocking factors and method of antiblocking immunotherapy in malignant tumors]. ( Basargin, ST; Glushkov, AN; Kliachkin, BM; Klimov, IA; Korostelev, AA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Shiiba, M | 1 |
| Yamagami, H | 1 |
| Yamamoto, A | 1 |
| Minakawa, Y | 1 |
| Okamoto, A | 1 |
| Kasamatsu, A | 1 |
| Sakamoto, Y | 1 |
| Uzawa, K | 1 |
| Takiguchi, Y | 1 |
| Tanzawa, H | 1 |
| Chao, TY | 1 |
| Ting, CS | 1 |
| Chu, TM | 1 |
| Yeh, MY | 1 |
| Kliachkin, BM | 1 |
| Basargin, ST | 1 |
| Glushkov, AN | 1 |
| Korostelev, AA | 1 |
| Klimov, IA | 1 |
| Kater, RM | 1 |
1 review available for mefenamic acid and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
1 trial available for mefenamic acid and Neoplasms
| Article | Year |
|---|---|
Double-blind evaluation of the analgesic and toxic effects of flufenamic acid and mefenamic acid in patients with chronic pain.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Flufenamic Acid; Fluorine; Humans; Mefenamic Acid; | 1968 |
3 other studies available for mefenamic acid and Neoplasms
| Article | Year |
|---|---|
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Memb | 2017 |
The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.
Topics: Aspirin; Cells, Cultured; Cytotoxicity, Immunologic; Dinoprostone; Humans; Indomethacin; Interleukin | 1993 |
[Mechanism of formation of blocking factors and method of antiblocking immunotherapy in malignant tumors].
Topics: 2,3-Diketogulonic Acid; Alloxan; Aminopyrine; Animals; Antigens, Neoplasm; Drug Combinations; Ferric | 1985 |